A placebo-controlled, government run trial of remdesivir to treat COVID-19 infection reportedly met its “primary efficacy endpoint” according to Gilead Sciences. While we are waiting for more information on the results, having shown efficacy in this large (800 patient), controlled trial could help to resolve the questions raised in prior testing of the drug.
More to come….
Hi great rreading your blog
LikeLiked by 1 person